Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS)

Pyxis Oncology, Inc. (NASDAQ:PYXS) saw some unusual options trading activity on Thursday. Traders purchased 4,270 put options on the company. This represents an increase of approximately 614% compared to the typical daily volume of 598 put options.

Pyxis Oncology Stock Down 26.3%

Shares of NASDAQ PYXS opened at $1.28 on Friday. The stock’s 50 day moving average price is $4.01 and its two-hundred day moving average price is $2.38. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55. The stock has a market capitalization of $79.38 million, a P/E ratio of -0.80 and a beta of 1.37.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01. On average, analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PYXS shares. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 price target for the company. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Guggenheim raised their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. HC Wainwright lifted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Institutional Trading of Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in shares of Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after buying an additional 9,062 shares during the last quarter. Vanguard Group Inc. raised its stake in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after acquiring an additional 14,566 shares during the period. Velan Capital Investment Management LP raised its stake in Pyxis Oncology by 37.5% during the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock worth $122,000 after acquiring an additional 15,000 shares during the period. Catalyst Funds Management Pty Ltd bought a new position in Pyxis Oncology in the second quarter worth about $26,000. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Pyxis Oncology in the second quarter valued at approximately $37,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.